Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

11.1%

2 terminated/withdrawn out of 18 trials

Success Rate

81.8%

-4.7% vs industry average

Late-Stage Pipeline

22%

4 trials in Phase 3/4

Results Transparency

11%

1 of 9 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

N/A

6(60.0%)

Phase 4

3(30.0%)

Phase 3

1(10.0%)

10Total

N/A(6)

Phase 4(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials

NCT06523530Phase 4Recruiting

Effect of a GnRH Analog on Hepatic Steatosis

Role: collaborator

NCT07372521Not Yet Recruiting

Measuring Small-Airways Disease Improvement After Step-up to Extrafine TRIple or High-dose ICS/LABA in Patients Uncontrolled on Medium Dose ICS/LABA eXploring T2 Inflammation

Role: collaborator

NCT07160348Not Yet Recruiting

Translation and Validation of the Hypoparathyroidism Patient Experience Scales (HPES) Questionnaire in Greek

Role: collaborator

NCT05493761Phase 4Active Not Recruiting

Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease

Role: collaborator

NCT06164795Recruiting

Sequential Therapies After Osteoanabolic Treatment

Role: lead

NCT05575167Recruiting

Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)

Role: lead

NCT04338529Completed

Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation

Role: collaborator

NCT04766151Phase 3Unknown

Nitrate Use to Obtain Radial Spasm Embarrassment (NURSE - TTS Trial)

Role: lead

NCT04206618Completed

Circulating Myokine Levels and Bone Metabolism

Role: lead

NCT04203212Completed

BMD Alterations and Bone and Muscle Parameters During Menstrual Cessation With GnRH

Role: lead

NCT02553746Not ApplicableCompleted

Ultrasound for Neuraxial Anesthesia

Role: lead

NCT02499237Phase 4Completed

Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation

Role: lead

NCT02765750Not ApplicableTerminated

Postoperative Outcomes After Positive Intraoperative Messages

Role: lead

NCT02556853Not ApplicableTerminated

Ultrasound for Double Lumen Endotracheal Tube

Role: lead

NCT03098667Not ApplicableCompleted

Laryngeal Mask Airway (LMA) Protector for Minimally Invasive Thyroidectomy

Role: lead

NCT02498431Not ApplicableCompleted

Serum Irisin in Myocardial Infraction and Following Percutaneous Coronary Intevention

Role: lead

NCT01986530Completed

Circulating Levels of Irisin in Healthy Young Subjects

Role: lead

NCT01572545Not ApplicableCompleted

Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone Mass

Role: collaborator

All 18 trials loaded